Skip to main content
. Author manuscript; available in PMC: 2019 Feb 20.
Published in final edited form as: Mol Pharm. 2016 Oct 18;13(11):3884–3890. doi: 10.1021/acs.molpharmaceut.6b00682

Figure 4.

Figure 4.

In silico predicted binding of 15-mer peptides derived from Flic or mFliC to mouse MHC-II allotypes H2-IAb/IAd using the IEDB method. Lower percentiles are indicative of stronger binding. Individual peptides from each protein are shown at top and bottom depending on their lysine inclusion status, which is necessary for hapten presentation. Curves represent rolling average likelihood of lysine inclusion at each predicted binding affinity.